Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...

Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ ...

It’s finally over. Medtronic and Boston Scientific’s Axonics longstanding patent battle is finished. The companies settled the legal spat over patent infringements related to sacral neuromodulation ...

Axonics, Inc. (NASDAQ:AXNX) rose 1.5% in after-hours trading after a jury voted in its favor in a patent dispute with Medtronic (MDT). Medtronic (MDT) was seeking $150 million in a patent dispute with ...

Raymond Cohen, co-founder of Axonics, can now breathe a sigh of relief. After a long delay tied to a federal probe of the Axonics sale, Boston Scientific Corp. (NYSE: BSX) announced Nov. 15 the ...

Boston Scientific Corporation plans to acquire Axonics, Inc. for $3.7 billion in cash to expand its urology offerings with Axonics' innovative urinary and bowel disorder treatments. Axonics, founded ...

Weighted-average shares used to compute basic and diluted net loss per share ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics, Inc. after entering into a purchase agreement in January. Axonics, a publicly traded ...